Drugs for Gastrointestinal Diseases Practice Questions

Q: Which of the following is NOT an H2 receptor antagonist?

Esomeprazole. ***Esomeprazole***- **Esomeprazole** is a **proton pump inhibitor (PPI)**, which works by irreversibly blocking the H+/K+-ATPase pump in gastric parietal cells, thereby reducing acid secretion [1].- All other options listed are H2 receptor antagonists, making esomeprazole the correct answer as it is *not* an H2 blocker [1, 2].*Ranitidine*- **Ranitidine** is an **H2 receptor antagonist** that competitively blocks histamine from binding to H2 receptors on parietal cells, leading to decreased gastric acid secretion [2].- It was commonly used for conditions like GERD and peptic ulcers, though its use has been restricted due to contamination concerns.*Famotidine*- **Famotidine** is also an **H2 receptor antagonist** that works similarly to ranitidine by blocking H2 receptors on parietal cells to reduce acid production [2].- It is frequently used for managing conditions associated with excess stomach acid.*Cimetidine*- **Cimetidine** is the **first-generation H2 receptor antagonist** that competitively inhibits histamine binding at H2 receptors on gastric parietal cells [2].- While effective for acid suppression, it has more drug interactions and side effects compared to newer H2 antagonists due to its inhibition of cytochrome P450 enzymes.

Q: For chemotherapy-induced vomiting, which 5-HT3 antagonist has the maximum potency?

Palonosetron. ***Palonosetron*** - Palonosetron is a **second-generation 5-HT3 antagonist** [1], [2] known for its **highest potency** and longer duration of action compared to first-generation agents [2]. - Its high affinity for the **5-HT3 receptor** and extended half-life make it particularly effective for both acute and delayed **chemotherapy-induced nausea and vomiting (CINV)** [3]. *Ondansetron* - Ondansetron is a **first-generation 5-HT3 antagonist** [1], [2] that is widely used, but it has a shorter half-life and lower receptor affinity than palonosetron [2]. - While effective for acute CINV, it is generally considered less potent for **delayed-phase CINV**. *Granisetron* - Granisetron is another **first-generation 5-HT3 antagonist** [1], [2] with a potency and duration of action comparable to ondansetron [3]. - It is effective for **acute CINV**, but its efficacy for delayed CINV is similar to other first-generation agents [2]. *Dolasetron* - Dolasetron is also a **first-generation 5-HT3 antagonist** [1], [2] that is available in intravenous and oral forms. - While effective for acute CINV, it does not demonstrate the same high potency or extended duration of action as palonosetron.

Q: Which of the following drugs is least likely to cause peptic ulcers?

Cyclosporine. ***Cyclosporine*** - Cyclosporine is an **immunosuppressant** that primarily acts by inhibiting **calcineurin**, which reduces T-cell activation. It is **least likely** to cause peptic ulcers among the choices. - While it has various side effects, gastrointestinal irritation or peptic ulceration is not a prominent or direct adverse effect compared to other listed drugs. *KCl* - **Potassium chloride (KCl)**, particularly in solid tablet form, can cause **direct mucosal injury** and **ulceration** in the esophagus and stomach if it dissolves slowly or is taken without adequate water. - This is due to its **hyperosmolar** nature and potential for local high concentrations of potassium ions. *Diclofenac* - **Diclofenac** is a **non-steroidal anti-inflammatory drug (NSAID)** that inhibits **COX-1 and COX-2 enzymes**, leading to reduced prostaglandin synthesis. - Reduced prostaglandins diminish the stomach's protective mucous barrier and bicarbonate secretion, making it highly prone to **peptic ulcer formation** and gastrointestinal bleeding. *Clopidogrel* - **Clopidogrel** is an **antiplatelet drug** that inhibits **ADP-induced platelet aggregation**, increasing the risk of bleeding throughout the body, including the gastrointestinal tract. - While it doesn't directly cause ulcers through mucosal damage like NSAIDs or KCl, its antiplatelet effect significantly **increases the risk of gastrointestinal bleeding** from any existing erosions or ulcers, which can complicate peptic ulcer disease.

Q: What is the mechanism of action of Tegaserod?

5HT4 receptor agonist. ***5HT4 receptor agonist*** - Tegaserod is a **selective serotonin 5-HT4 receptor partial agonist** that facilitates the release of neurotransmitters. - This action **stimulates the peristaltic reflex** and intestinal secretion, thereby accelerating intestinal transit and alleviating symptoms of **irritable bowel syndrome with constipation (IBS-C)**. *5HT3 receptor antagonist* - **5-HT3 receptor antagonists** (e.g., ondansetron) are primarily used as **antiemetics** to prevent nausea and vomiting. - They work by blocking serotonin's action at 5-HT3 receptors in the gastrointestinal tract and the **chemoreceptor trigger zone** in the brain. *Dopamine D2 receptor antagonist* - **Dopamine D2 receptor antagonists** (e.g., metoclopramide) are used as **prokinetics** and antiemetics due to their ability to block dopamine's inhibitory effect on gastrointestinal motility. - They increase **gastric emptying** and intestinal transit, but this is not the primary mechanism of tegaserod. *NK1 receptor antagonist* - **Neurokinin-1 (NK1) receptor antagonists** (e.g., aprepitant) are primarily used for their **antiemetic properties**, particularly in chemotherapy-induced nausea and vomiting. - They block the action of **substance P** at the NK1 receptor, which is involved in the emetic reflex.

Q: Which of the following best describes the mechanism of action of Lubiprostone?

Chloride channel activator. ***Chloride channel activator*** - Lubiprostone is a **prostaglandin E1 derivative** that specifically activates **chloride channels (ClC-2)** on the apical membrane of intestinal epithelial cells. - This activation leads to an increase in **fluid secretion into the intestinal lumen**, softening stool and promoting bowel movements. *Chloride channel inhibitor* - Medications that inhibit chloride channels would likely **reduce fluid secretion** in the intestines, potentially worsening constipation. - This mechanism is **opposite** to the therapeutic effect of lubiprostone, which aims to increase fluid content in the stool. *Sodium channel activator* - Activating sodium channels in the intestine could lead to increased fluid absorption or altered electrolyte balance, but this is **not the primary mechanism** of action for lubiprostone. - Lubiprostone's effect is centered around **anion (chloride) secretion**, not direct sodium channel activation. *Sodium channel inhibitor* - Inhibiting sodium channels might reduce sodium absorption, potentially increasing luminal water, but this is **not how lubiprostone works**. - Lubiprostone specifically targets **chloride channels** to achieve its cathartic effect.

Q: A patient with diabetic gastroparesis is treated with erythromycin primarily due to its ability to:

Bind to motilin receptors. ***Bind to motilin receptors*** - Erythromycin acts as a **motilin receptor agonist**, mimicking the action of the endogenous hormone motilin, which stimulates gastrointestinal motility. - This binding leads to increased **gastric contractions** and improved gastric emptying, addressing the primary problem in gastroparesis. *Increase gastric motility* - While erythromycin *does* increase gastric motility, this option describes the **effect** rather than the primary mechanism of action (binding to motilin receptors). - Understanding the receptor binding is crucial for grasping why erythromycin is effective in this context. *Decrease gastric motility* - Decreasing gastric motility would **worsen** diabetic gastroparesis, a condition already characterized by delayed gastric emptying. - Erythromycin's therapeutic effect is the exact opposite of decreasing motility. *Act as a motilin analogue* - Erythromycin is not a direct motilin analogue in terms of its chemical structure, but it **mimics motilin's effects** by binding to its receptors. - The precise mechanism is its binding to the receptors, rather than being classified as a structural analogue.

Q: Which of the following is an H2 receptor antagonist used as an anti-ulcer drug?

Famotidine. ***Famotidine*** - **Famotidine** is a potent and selective **H2 receptor antagonist** that works by blocking histamine H2 receptors on parietal cells, thereby reducing gastric acid secretion. - It is widely used for the treatment of **peptic ulcers**, gastroesophageal reflux disease (**GERD**), and other acid-related disorders. *Pirenzepine* - **Pirenzepine** is a **selective M1 muscarinic antagonist**, which inhibits gastric acid secretion by blocking cholinergic pathways. - While it was previously used as an anti-ulcer drug, its mechanism of action is distinct from H2 receptor antagonism. *Rabeprazole* - **Rabeprazole** is a **proton pump inhibitor (PPI)** that irreversibly blocks the H+/K+-ATPase pump in gastric parietal cells, leading to a profound and prolonged reduction in gastric acid production. - Its mechanism is different from H2 receptor antagonists. *Sucralfate* - **Sucralfate** is a **cytoprotective agent** that forms a viscous, protective gel that adheres to ulcerated areas, shielding them from acid, pepsin, and bile. - It does not directly inhibit acid secretion but rather provides a physical barrier and promotes healing.

Q: Constipation is a possible side effect of drugs taken by the oral route. Which of the following medications is least likely to cause constipation?

docusate. ***docusate*** - **Docusate** is a **stool softener** and is actually used to prevent and treat constipation, making it the least likely to cause it. - It works by increasing the amount of water and fat the stool absorbs, making it easier to pass. *promethazine* - **Promethazine** is an antihistamine with **anticholinergic properties** that can slow down gut motility. - Reduced gastrointestinal motility is a common side effect of drugs with anticholinergic effects, leading to **constipation**. *loperamide* - **Loperamide** is an **opioid receptor agonist** that works by slowing down gut contractions. - It is specifically used as an **antidiarrheal medication**, and constipation is a well-known side effect of its action. *diphenhydramine* - **Diphenhydramine** is an antihistamine with significant **anticholinergic effects**. - Its anticholinergic action reduces intestinal motility and secretions, frequently causing **constipation**.

Q: Antacid drug that typically causes diarrhea.

Magnesium hydroxide. ***Magnesium hydroxide*** - **Magnesium-containing antacids** commonly cause **diarrhea** due to their osmotic laxative effect, drawing water into the intestines. - The magnesium ions are poorly absorbed and act as an **osmotic agent** in the gut lumen. *Sodium bicarbonate* - **Sodium bicarbonate** can cause **systemic alkalosis** due to absorption of bicarbonate ions, especially with high doses or impaired renal function. - It does not typically cause diarrhea; instead, the CO2 produced from its reaction with stomach acid can cause **belching** and gastric distension. *Calcium carbonate* - **Calcium carbonate** is more frequently associated with **constipation** due to calcium's ability to slow intestinal motility. - Excessive use can lead to **hypercalcemia** and milk-alkali syndrome. *Aluminium hydroxide* - **Aluminium-containing antacids** are notorious for causing **constipation** by slowing gut motility. - Long-term use can also lead to **hypophosphatemia** as aluminum binds to phosphate in the GI tract.

Q: A 56-year-old woman has nausea due to chemotherapy for breast cancer. Droperidol is effective in reducing nausea because it blocks which of the following?

Dopamine receptors in the CTZ. **Dopamine receptors in the CTZ** - Droperidol is a **butyrophenone antipsychotic** that acts as an **antidopaminergic agent**, primarily targeting **D2 dopamine receptors**. - Its antiemetic effect is mainly due to blocking these **dopamine receptors in the chemoreceptor trigger zone (CTZ)**, which is involved in initiating the vomiting reflex. *Glucocorticoid receptors in the vomiting center* - **Glucocorticoids** like dexamethasone are used as antiemetics, but they act via **glucocorticoid receptors**, not through dopamine receptor blockade. - Their mechanism involves inhibiting prostaglandin synthesis and inflammation, reducing the release of serotonin. *ACh receptors in the periphery* - Drugs that block **acetylcholine (ACh) receptors** (e.g., scopolamine) are used for motion sickness, but they are not the primary mechanism of action for droperidol. - **Anticholinergics** typically exert their effects on the vestibular system and peripheral muscarinic receptors. *5-HT 2 receptors in the CTZ* - While some antiemetics (e.g., **ondansetron**) block **serotonin (5-HT3) receptors**, droperidol's primary action is not on **5-HT2 receptors**. - **Serotonin antagonists** are particularly effective for chemotherapy-induced nausea and vomiting as chemotherapy often releases serotonin from enterochromaffin cells.

Question 1

Which of the following is NOT an H2 receptor antagonist?

Accepted Answer

Esomeprazole

Answer

Cimetidine

Answer

Ranitidine

Answer

Famotidine

Question 2

For chemotherapy-induced vomiting, which 5-HT3 antagonist has the maximum potency?

Accepted Answer

Palonosetron

Answer

Ondansetron

Answer

Granisetron

Answer

Dolasetron

Question 3

Which of the following drugs is least likely to cause peptic ulcers?

Accepted Answer

Cyclosporine

Answer

KCl

Answer

Diclofenac

Answer

Clopidogrel

Question 4

What is the mechanism of action of Tegaserod?

Accepted Answer

5HT4 receptor agonist

Answer

5HT3 receptor antagonist

Answer

Dopamine D2 receptor antagonist

Answer

NK1 receptor antagonist

Question 5

Which of the following best describes the mechanism of action of Lubiprostone?

Accepted Answer

Chloride channel activator

Answer

Chloride channel inhibitor

Answer

Sodium channel activator

Answer

Sodium channel inhibitor

Question 6

A patient with diabetic gastroparesis is treated with erythromycin primarily due to its ability to:

Accepted Answer

Bind to motilin receptors

Answer

Increase gastric motility

Answer

Decrease gastric motility

Answer

Act as a motilin analogue

Question 7

Which of the following is an H2 receptor antagonist used as an anti-ulcer drug?

Accepted Answer

Famotidine

Answer

Pirenzepine

Answer

Rabeprazole

Answer

Sucralfate

Question 8

Constipation is a possible side effect of drugs taken by the oral route. Which of the following medications is least likely to cause constipation?

Accepted Answer

docusate

Answer

promethazine

Answer

loperamide

Answer

diphenhydramine

Question 9

Antacid drug that typically causes diarrhea.

Accepted Answer

Magnesium hydroxide

Answer

Sodium bicarbonate

Answer

Calcium carbonate

Answer

Aluminium hydroxide

Question 10

A 56-year-old woman has nausea due to chemotherapy for breast cancer. Droperidol is effective in reducing nausea because it blocks which of the following?

Accepted Answer

Dopamine receptors in the CTZ

Answer

Glucocorticoid receptors in the vomiting center

Answer

ACh receptors in the periphery

Answer

5-HT3 receptors in the CTZ

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?